Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences’ Real World Data on Endari Accepted for E-Poster at the 62nd Annual Scientific Meeting of the British Society for HaematologyMarch 04, 2022

Emmaus Life Sciences, Inc. today announced that real world data on Endari®, the company’s prescription-grade L-glutamine oral powder for the treatment of sickle cell disease, has been accepted for an e-poster at the 62nd Annual Meeting of the British Society for Haematology (BSH) to be held April 3 -5, 2022 at the Manchester Central in Manchester, England and virtually.

Emmaus Life Sciences to Present at the H.C. Wainwright BioConnect ConferenceJanuary 04, 2022

Emmaus Life Sciences, Inc. today announced that Yutaka Niihara, M.D., M.P.H, Chairman and Chief Executive Officer of Emmaus, will present a company overview at the H.C. Wainwright BioConnect Conference, being held virtually, January 10-13, 2022

Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual MeetingDecember 14, 2021

Analysis Indicates that Patients Requiring Blood Transfusions and Receiving Endari Required ~43% Fewer Units of Red Blood Cells

Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16thDecember 09, 2021

Emmaus invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Emmaus Life Sciences' Data on Endari Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & ExhibitionDecember 07, 2021

Emmaus Life Sciences, Inc. today announced that data on Endari® has been accepted for a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exhibition.